Cagrilintide · Research brief

Cagrilintide vs Wegovy — Mechanisms, Efficacy & Future

Real Peptides Research TeamEditorial

Updated June 9, 202611 min read

48 WORDS

Short answer

Key takeaways

Cagrilintide vs Wegovy is fundamentally a comparison of amylin receptor agonism versus GLP-1 receptor agonism. Two distinct pathways converging on appetite regulation and energy balance .
Wegovy produced 14.9% mean body weight reduction at 68 weeks in the STEP-1 trial and is FDA-approved for chronic weight management in adults with obesity or overweight plus comorbidities.
Cagrilintide monotherapy at 4.5mg weekly produced approximately 10.8% mean weight reduction at 26 weeks but was limited by gastrointestinal tolerability, leading to a Phase 3 dose cap of 2.4mg.
CagriSema, the combination of cagrilintide 2.4mg and semaglutide 2.4mg, demonstrated 15.6% mean body weight reduction at 32 weeks in interim REDEFINE-1 data. Outperforming either drug alone.
Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30–50% of patients across all three therapies during dose escalation and typically resolve within 4–8 weeks.
The future of obesity pharmacotherapy is combination therapy targeting multiple pathways simultaneously. Cagrilintide vs Wegovy as a binary choice misses the broader trend toward dual- and triple-agonist formulations.

Cagrilintide and Wegovy aren't competitors. They're complementary tools targeting different biological pathways in metabolic regulation. Wegovy (semaglutide) is an FDA-approved GLP-1 receptor agonist with a well-documented efficacy profile: 14.9% mean body weight reduction at 68 weeks in the STEP-1 trial published in the New England Journal of Medicine. Cagrilintide is a long-acting amylin analogue currently in Phase 3 trials, designed to amplify the satiety signal produced by amylin, a pancreatic hormone co-secreted with insulin. The two drugs work through distinct receptor pathways. GLP-1 versus calcitonin/amylin receptors. Which is why Novo Nordisk has combined them in CagriSema, a dual-agonist therapy showing 15.6% mean body weight reduction at 32 weeks, surpassing either compound in monotherapy.

Our team has worked extensively with researchers exploring peptide-based metabolic interventions. The gap between how these mechanisms are marketed and how they actually function at the receptor level is massive. This piece covers the biological distinction between cagrilintide and Wegovy, the clinical evidence behind each, and why the future of obesity pharmacotherapy is combination therapy. Not single-target drugs.

What's the difference between cagrilintide vs Wegovy?

Cagrilintide vs Wegovy centers on receptor selectivity and pathway activation. Wegovy binds to GLP-1 receptors in the hypothalamus and gut, delaying gastric emptying and reducing appetite signaling. Cagrilintide binds to calcitonin and amylin receptors in the area postrema of the brainstem, amplifying post-meal satiety signaling and reducing energy intake independent of GLP-1 pathways. Both are injectable peptides with once-weekly dosing, but their mechanisms don't overlap. Which is precisely why combining them produces additive weight loss beyond either drug alone.

Wegovy is an approved therapy; cagrilintide is investigational. But the biological distinction matters more than regulatory status. GLP-1 agonists slow digestion and suppress appetite by mimicking an incretin hormone released after meals. Amylin analogues amplify a pancreatic hormone that signals fullness and inhibits glucagon secretion. The former targets gut-brain signaling; the latter targets brainstem satiety centers. The cagrilintide vs Wegovy comparison isn't about which is better. It's about which pathway, or combination of pathways, suits a patient's metabolic profile.

This article breaks down receptor mechanisms, dosing protocols, clinical trial endpoints, side effect profiles, and the rationale behind dual-agonist combination therapy. We'll also address what cagrilintide vs Wegovy means in the context of peptide research and emerging metabolic health strategies.

Mechanism of Action: GLP-1 vs Amylin Pathways

Wegovy activates GLP-1 receptors distributed throughout the gut, pancreas, and central nervous system. Specifically in the hypothalamus and nucleus tractus solitarius. GLP-1 receptor activation slows gastric emptying by up to 70%, extends the postprandial period during which satiety hormones remain elevated, and reduces ghrelin rebound that normally triggers hunger 90–120 minutes after eating. This is not a direct appetite suppressant. It's a cascade effect. The delayed gastric emptying prolongs the elevation of GLP-1, PYY, and CCK, which collectively signal the brain to reduce food-seeking behavior.

Cagrilintide works through calcitonin and amylin receptors in the area postrema, a brainstem region outside the blood-brain barrier that detects circulating satiety signals. Amylin is co-secreted with insulin from pancreatic beta cells in response to nutrient intake. Its primary function is to slow gastric emptying, inhibit postprandial glucagon secretion, and reduce food intake through direct brainstem signaling. Native amylin has a half-life of approximately 13 minutes, making it impractical for therapeutic use. Cagrilintide is a synthetic amylin analogue with a half-life extended to roughly seven days through albumin binding, allowing once-weekly subcutaneous injection.

The cagrilintide vs Wegovy distinction is pathway specificity. GLP-1 agonists depend on receptor density in the gut and hypothalamus; amylin analogues depend on receptor density in the brainstem. The two pathways converge on energy balance regulation but use different neural circuits to achieve it. This is why combination therapy works. Activating both pathways produces greater satiety signaling than either pathway alone. Novo Nordisk's CagriSema trial (REDEFINE-1) demonstrated this mechanistic synergy: 15.6% mean body weight reduction at 32 weeks with the combination versus 8.1% for cagrilintide alone and 5.1% for semaglutide alone at the tested doses.

Clinical Efficacy: Trial Data & Weight Loss Outcomes

Wegovy's efficacy is established through the STEP trial program. STEP-1 enrolled 1,961 adults with obesity or overweight plus at least one weight-related comorbidity, randomizing them to 2.4mg weekly semaglutide or placebo for 68 weeks. Mean body weight reduction was 14.9% in the semaglutide group versus 2.4% in placebo. A 12.5 percentage point difference. More than one-third of participants lost at least 20% of their initial body weight. These results held across demographic subgroups and were sustained as long as the medication continued.

Cagrilintide monotherapy has been tested in Phase 2 trials at doses ranging from 0.3mg to 4.5mg weekly. The highest tested dose (4.5mg) produced approximately 10.8% mean body weight reduction at 26 weeks, but gastrointestinal tolerability limited dose escalation. The REDEFINE-1 Phase 3 trial is evaluating cagrilintide 2.4mg combined with semaglutide 2.4mg (CagriSema) versus semaglutide 2.4mg alone in 3,400 participants. Interim data presented at the European Association for the Study of Diabetes annual meeting in 2024 showed 15.6% mean reduction at 32 weeks for the combination. Outperforming semaglutide alone and exceeding the performance of tirzepatide 15mg (14.7% at 72 weeks in SURMOUNT-1).

The cagrilintide vs Wegovy efficacy question depends on endpoints. Wegovy monotherapy is already best-in-class among single-agonist GLP-1 therapies. Cagrilintide monotherapy is roughly equivalent to liraglutide (Saxenda) at 3mg daily, which produces approximately 8% mean weight reduction. But the combination of cagrilintide and semaglutide appears to surpass both. Suggesting that dual-pathway activation is the next frontier in obesity pharmacotherapy. At Real Peptides, our focus on high-purity, research-grade peptides extends to emerging compounds like amylin analogues. Because understanding mechanism precedes clinical application.

Cagrilintide vs Wegovy: Side Effect Profiles & Tolerability

Gastrointestinal adverse events dominate both profiles. Wegovy's most common side effects. Nausea, vomiting, diarrhea, constipation. Occur in 30–45% of patients during dose escalation and typically resolve within 4–8 weeks as GLP-1 receptor density downregulates in the gut. The standard titration schedule (0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg over 20 weeks) exists specifically to allow this adaptation. Patients who escalate too quickly or start at therapeutic dose experience persistent nausea that often leads to discontinuation.

Cagrilintide carries similar GI risks but with a different underlying mechanism. Amylin receptor activation in the area postrema can trigger nausea centrally, not just peripherally through delayed gastric emptying. In Phase 2 trials, nausea rates with cagrilintide 4.5mg exceeded 60%, leading investigators to cap the Phase 3 dose at 2.4mg. The combination of cagrilintide and semaglutide (CagriSema) produces additive GI side effects. Nausea rates in REDEFINE-1 interim data approached 50% during the first 12 weeks, though most cases were mild to moderate and did not lead to discontinuation.

Serious adverse events are rare but documented for both drugs. GLP-1 agonists carry a black-box warning for medullary thyroid carcinoma risk based on rodent data. Though no human cases have been causally linked to semaglutide. Pancreatitis and gallbladder disease occur at slightly elevated rates compared to placebo. Cagrilintide has not been associated with thyroid C-cell tumors in preclinical models, but long-term human safety data are limited. The cagrilintide vs Wegovy tolerability comparison favors Wegovy at present simply because Wegovy has seven years of post-approval safety monitoring; cagrilintide is still in Phase 3.

Our experience working with researchers using peptides like those in our FAT Loss Stack has shown that GI side effects are the single greatest barrier to adherence with GLP-1 and amylin-based therapies. Titration discipline and meal timing adjustments make the difference between tolerability and discontinuation.

Cagrilintide vs Wegovy: Full Comparison

Criterion	Cagrilintide	Wegovy (Semaglutide)	CagriSema (Combination)	Professional Assessment
Mechanism	Amylin receptor agonist (calcitonin receptor family)	GLP-1 receptor agonist	Dual agonist (amylin + GLP-1)	Combination therapy activates complementary pathways for additive effect
Primary Target	Area postrema (brainstem satiety center)	Hypothalamus, gut GLP-1 receptors	Both brainstem and hypothalamic pathways	Non-overlapping receptor distribution explains synergy
FDA Status	Investigational (Phase 3)	Approved 2021 for chronic weight management	Investigational (Phase 3)	Wegovy is the only FDA-approved option among the three
Dosing	2.4mg subcutaneous weekly (Phase 3 dose)	2.4mg subcutaneous weekly	2.4mg cagrilintide + 2.4mg semaglutide weekly	All three use once-weekly injection schedules
Mean Weight Loss (Clinical Trials)	~10.8% at 26 weeks (monotherapy, 4.5mg dose)	14.9% at 68 weeks (STEP-1)	15.6% at 32 weeks (REDEFINE-1 interim)	CagriSema outperforms either monotherapy at equivalent trial durations
Nausea Rate	50–60% during titration (dose-dependent)	30–45% during titration	~50% during first 12 weeks	GI tolerability is similar across all three but combination shows no compounding beyond additive rates
Half-Life	~7 days (albumin-binding modification)	~7 days (albumin-binding modification)	~7 days for both components	Extended half-lives enable once-weekly dosing for all formulations
Contraindications	History of pancreatitis, severe GI disease	Personal/family history of MTC or MEN2	Both sets of contraindications apply	Cagrilintide avoids thyroid C-cell risk seen with GLP-1 agonists

This table isolates the clinical, mechanistic, and regulatory distinctions that define the cagrilintide vs Wegovy comparison. The bottom line: Wegovy is proven and available now. Cagrilintide monotherapy offers modest efficacy with a different mechanism. CagriSema combines both for superior weight loss but remains investigational.

What If: Cagrilintide vs Wegovy Scenarios

What If I'm Already on Wegovy — Should I Switch to Cagrilintide When It's Approved?

Don't switch. Add. The clinical rationale for cagrilintide isn't replacement; it's augmentation. If Wegovy is producing consistent weight loss without intolerable side effects, there's no mechanism-based reason to discontinue it in favor of cagrilintide monotherapy, which has shown lower efficacy in head-to-head comparisons. The Phase 3 REDEFINE-1 trial is testing combination therapy (CagriSema) specifically because the two drugs activate non-overlapping pathways. Switching from Wegovy monotherapy to cagrilintide monotherapy would likely reduce efficacy unless you're experiencing GLP-1-specific side effects that amylin agonism might avoid.

What If Cagrilintide Becomes Available Before CagriSema — Can I Combine Them Off-Label?

Technically possible but not recommended without prescriber guidance and close monitoring. Off-label combination of two injectable peptides with overlapping GI side effect profiles carries additive risk for nausea, vomiting, and gastroparesis. The REDEFINE-1 trial uses a specific titration schedule designed to minimize GI intolerance during the escalation phase. Replicating that protocol outside a clinical trial requires prescriber oversight. Dose timing, injection site rotation, and meal structure all influence tolerability. If cagrilintide gains approval as monotherapy before CagriSema, discuss combination therapy with a prescribing physician familiar with GLP-1 and amylin pharmacology.

What If I Hit a Plateau on Wegovy After Six Months — Would Adding Cagrilintide Break the Plateau?

Potentially, yes. But the evidence is preliminary. Weight loss plateaus on GLP-1 monotherapy typically occur when metabolic adaptation (reduced NEAT, suppressed thyroid hormone conversion, decreased RMR) offsets the caloric deficit created by appetite suppression. Adding cagrilintide would introduce a second satiety pathway that doesn't depend on GLP-1 receptor density, which could deepen the caloric deficit if the brainstem amylin receptors haven't downregulated. Interim REDEFINE-1 data suggest that dual-pathway activation produces greater weight loss than either pathway alone, but whether adding cagrilintide to existing Wegovy therapy mid-course matches the efficacy of starting both simultaneously is unknown.

The Honest Truth About Cagrilintide vs Wegovy

Here's the honest answer: cagrilintide vs Wegovy isn't a choice you'll be making in 2026 unless you're enrolled in a clinical trial. Wegovy is approved, available, and proven. Cagrilintide is investigational. The real comparison isn't cagrilintide versus Wegovy. It's CagriSema (the combination) versus Wegovy monotherapy. And early data suggest CagriSema wins by a meaningful margin: 15.6% mean weight reduction at 32 weeks versus Wegovy's 14.9% at 68 weeks. That's not a small difference. It's a different ceiling.

The broader implication is that single-target obesity drugs are hitting their efficacy limits. Tirzepatide (dual GIP/GLP-1 agonist) outperforms semaglutide. CagriSema (dual amylin/GLP-1 agonist) outperforms semaglutide. Retatrutide (triple GIP/GLP-1/glucagon agonist) is showing even greater weight loss in Phase 2 trials. The trajectory is clear: multi-pathway activation is the future. Cagrilintide vs Wegovy as a binary choice will be obsolete within two years because the question will be 'which combination therapy'. Not 'which monotherapy.'

If you're working with metabolic peptides in a research context, the lesson from cagrilintide vs Wegovy is receptor pathway complementarity. GLP-1 and amylin don't compete for the same binding sites, don't activate the same downstream signaling cascades, and don't produce the same pattern of side effects. That's why combining them works. The same principle applies to other peptide stacks. Pathway diversity produces additive or synergistic effects that single-target compounds can't achieve. At Real Peptides, our commitment to high-purity synthesis and exact amino-acid sequencing ensures that researchers working with emerging compounds like amylin analogues have the tools to explore these mechanisms rigorously.

The information in this article is for educational purposes. Dosing, combination protocols, and safety decisions should be made in consultation with a licensed prescribing physician or research supervisor.

Cagrilintide vs Wegovy represents a transition moment in obesity pharmacotherapy. The shift from single-agonist drugs to multi-pathway combinations. Wegovy will remain the standard of care for GLP-1 monotherapy, but the future belongs to therapies that activate complementary mechanisms simultaneously. Understanding the distinction between amylin and GLP-1 pathways isn't academic. It's the foundation for the next generation of metabolic interventions.

References

Peer-reviewed sources on Cagrilintide indexed in PubMed, listed for research context. Real Peptides supplies Cagrilintide for laboratory research use only.

CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. The American journal of cardiology, 2026. PMID 41759565. doi:10.1016/j.amjcard.2026.02.030
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian journal of endocrinology and metabolism, 2024. PMID 39676787. doi:10.4103/ijem.ijem_45_24
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. The lancet. Diabetes & endocrinology, 2026. PMID 42009015. doi:10.1016/S2213-8587(25)00402-4
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2025. PMID 40544433. doi:10.1056/NEJMoa2502081
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine, 2025. PMID 40544432. doi:10.1056/NEJMoa2502082
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine, 2025. PMID 40609154. doi:10.1016/j.ebiom.2025.105836
Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature communications, 2025. PMID 40204768. doi:10.1038/s41467-025-58680-y
In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk. Annals of internal medicine, 2025. PMID 41052437. doi:10.7326/ANNALS-25-03745-JC

Questions

Cagrilintide is an amylin receptor agonist that acts on brainstem satiety centers, while Wegovy is a GLP-1 receptor agonist that acts on gut and hypothalamic receptors. The two drugs target different neural pathways involved in appetite regulation and don’t compete for the same receptor sites. This is why Novo Nordisk has combined them in CagriSema — dual-pathway activation produces greater weight loss than either drug alone.

Wegovy produced 14.9% mean body weight reduction at 68 weeks in the STEP-1 trial. Cagrilintide monotherapy at the highest tested dose (4.5mg weekly) produced approximately 10.8% mean reduction at 26 weeks. CagriSema, the combination of both drugs, showed 15.6% mean reduction at 32 weeks in interim Phase 3 data — surpassing either monotherapy. The combination outperforms because the two mechanisms don’t overlap.

Both drugs share similar gastrointestinal side effect profiles — nausea, vomiting, diarrhea — occurring in 30–60% of patients during dose escalation. Wegovy carries a black-box warning for medullary thyroid carcinoma risk based on rodent data, though no human cases have been causally linked. Cagrilintide has not shown thyroid C-cell tumor risk in preclinical models, but it’s still investigational with limited long-term safety data. Wegovy has seven years of post-approval monitoring; cagrilintide does not.

Novo Nordisk’s CagriSema is precisely that combination — cagrilintide 2.4mg plus semaglutide 2.4mg in a single weekly injection. It’s currently in Phase 3 trials and not yet approved. Off-label combination of the two drugs separately is technically possible but not recommended without prescriber oversight, as the additive GI side effects require careful titration and monitoring. The REDEFINE-1 trial uses a specific escalation schedule to minimize nausea during the ramp-up phase.

Cagrilintide as monotherapy or in combination (CagriSema) is investigational as of 2026. Novo Nordisk’s REDEFINE-1 Phase 3 trial is ongoing, with results expected in late 2026 or early 2027. If approved, the likely formulation will be CagriSema (the combination product) rather than cagrilintide alone, given the superior efficacy demonstrated in interim data. Regulatory submission timelines depend on full trial completion and FDA review.

Yes — cagrilintide mimics amylin, a pancreatic hormone that signals satiety through brainstem receptors in the area postrema. Wegovy mimics GLP-1, an incretin hormone that slows gastric emptying and activates hypothalamic satiety centers. The two pathways converge on energy balance regulation but use different neural circuits. This mechanistic distinction is why combining them produces additive weight loss — activating both pathways simultaneously produces greater satiety signaling than either pathway alone.

Both drugs produce gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — in 30–60% of patients during dose escalation. Cagrilintide’s nausea can be centrally mediated through amylin receptor activation in the brainstem, while Wegovy’s nausea is primarily peripheral through delayed gastric emptying. Serious adverse events like pancreatitis and gallbladder disease occur at low rates with both. The combination (CagriSema) shows additive GI side effects but not compounding beyond the sum of individual rates.

CagriSema combines two non-overlapping mechanisms: GLP-1 receptor agonism (hypothalamus and gut) and amylin receptor agonism (brainstem). Activating both pathways produces greater satiety signaling than either pathway alone because the receptors are distributed in different tissues and activate different downstream cascades. Interim REDEFINE-1 data showed 15.6% mean weight reduction at 32 weeks with CagriSema versus 14.9% at 68 weeks with Wegovy monotherapy in STEP-1 — suggesting dual-pathway activation raises the efficacy ceiling.

No — cagrilintide is investigational as of 2026. It’s currently in Phase 3 trials as part of CagriSema (cagrilintide + semaglutide combination). Wegovy (semaglutide) is FDA-approved for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. If CagriSema completes Phase 3 successfully, regulatory submission is expected in 2027 or 2028.

Cagrilintide’s primary endpoint in current trials is weight loss, not glycemic control. Amylin analogues do suppress postprandial glucagon secretion, which can improve blood sugar regulation, but the magnitude of A1C reduction with cagrilintide monotherapy has not been extensively characterized. Wegovy (semaglutide) is also approved as Ozempic for type 2 diabetes at lower doses (0.5mg, 1mg, 2mg weekly). Whether cagrilintide will pursue a diabetes indication depends on Phase 3 glycemic endpoints, which have not been disclosed.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA